Boston Scientific Current Ratio 2011-2025 | BSX
Current and historical current ratio for Boston Scientific (BSX) from 2011 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Boston Scientific current ratio for the three months ending September 30, 2025 was 0.00.
| Boston Scientific Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2025-09-30 | $0.00B | 0.00 | |
| 2025-06-30 | $7.12B | $5.19B | 1.37 |
| 2025-03-31 | $7.34B | $5.06B | 1.45 |
| 2024-12-31 | $6.92B | $6.40B | 1.08 |
| 2024-09-30 | $8.76B | $5.91B | 1.48 |
| 2024-06-30 | $8.99B | $5.58B | 1.61 |
| 2024-03-31 | $8.19B | $4.92B | 1.67 |
| 2023-12-31 | $6.51B | $4.93B | 1.32 |
| 2023-09-30 | $6.50B | $4.58B | 1.42 |
| 2023-06-30 | $5.89B | $4.56B | 1.29 |
| 2023-03-31 | $5.70B | $4.08B | 1.40 |
| 2022-12-31 | $5.76B | $3.80B | 1.52 |
| 2022-09-30 | $5.14B | $3.55B | 1.45 |
| 2022-06-30 | $5.08B | $3.88B | 1.31 |
| 2022-03-31 | $5.07B | $4.28B | 1.19 |
| 2021-12-31 | $6.32B | $4.27B | 1.48 |
| 2021-09-30 | $6.23B | $4.02B | 1.55 |
| 2021-06-30 | $6.76B | $4.07B | 1.66 |
| 2021-03-31 | $6.10B | $3.39B | 1.80 |
| 2020-12-31 | $6.69B | $3.68B | 1.82 |
| 2020-09-30 | $6.16B | $3.30B | 1.87 |
| 2020-06-30 | $5.80B | $3.11B | 1.87 |
| 2020-03-31 | $4.82B | $3.98B | 1.21 |
| 2019-12-31 | $4.70B | $4.87B | 0.97 |
| 2019-09-30 | $4.85B | $4.25B | 1.14 |
| 2019-06-30 | $6.33B | $4.85B | 1.31 |
| 2019-03-31 | $6.23B | $4.48B | 1.39 |
| 2018-12-31 | $4.00B | $5.26B | 0.76 |
| 2018-09-30 | $3.97B | $5.08B | 0.78 |
| 2018-06-30 | $3.93B | $4.75B | 0.83 |
| 2018-03-31 | $4.08B | $4.99B | 0.82 |
| 2017-12-31 | $3.82B | $5.65B | 0.68 |
| 2017-09-30 | $3.48B | $4.83B | 0.72 |
| 2017-06-30 | $3.22B | $4.30B | 0.75 |
| 2017-03-31 | $3.03B | $3.49B | 0.87 |
| 2016-12-31 | $3.24B | $3.59B | 0.90 |
| 2016-09-30 | $3.18B | $3.02B | 1.06 |
| 2016-06-30 | $3.33B | $3.18B | 1.05 |
| 2016-03-31 | $3.16B | $2.61B | 1.21 |
| 2015-12-31 | $3.47B | $2.43B | 1.43 |
| 2015-09-30 | $3.46B | $2.24B | 1.55 |
| 2015-06-30 | $3.77B | $1.94B | 1.95 |
| 2015-03-31 | $3.19B | $2.46B | 1.30 |
| 2014-12-31 | $3.61B | $2.85B | 1.27 |
| 2014-09-30 | $3.18B | $1.82B | 1.75 |
| 2014-06-30 | $3.21B | $1.77B | 1.81 |
| 2014-03-31 | $2.94B | $1.72B | 1.71 |
| 2013-12-31 | $3.01B | $1.82B | 1.65 |
| 2013-09-30 | $3.53B | $1.90B | 1.85 |
| 2013-06-30 | $3.50B | $2.48B | 1.41 |
| 2013-03-31 | $3.10B | $1.64B | 1.90 |
| 2012-12-31 | $3.02B | $1.77B | 1.71 |
| 2012-09-30 | $3.17B | $1.82B | 1.75 |
| 2012-06-30 | $3.11B | $1.79B | 1.73 |
| 2012-03-31 | $3.09B | $1.67B | 1.85 |
| 2011-12-31 | $3.11B | $1.81B | 1.72 |
| 2011-09-30 | $3.21B | $1.89B | 1.70 |
| 2011-06-30 | $3.15B | $1.89B | 1.66 |
| 2011-03-31 | $3.57B | $2.04B | 1.75 |
| 2010-12-31 | $3.62B | $2.61B | 1.39 |
| 2010-09-30 | $3.56B | $2.96B | 1.20 |
| 2010-06-30 | $3.99B | $3.72B | 1.07 |
| 2010-03-31 | $3.75B | $2.91B | 1.29 |
| 2009-12-31 | $4.60B | $3.02B | 1.52 |
| 2009-09-30 | $4.96B | $3.18B | 1.56 |
| 2009-06-30 | $4.80B | $2.75B | 1.74 |
| 2009-03-31 | $4.57B | $2.43B | 1.88 |
| 2008-12-31 | $5.45B | $3.23B | 1.69 |
| 2008-09-30 | $5.29B | $3.54B | 1.49 |
| 2008-06-30 | $5.17B | $3.04B | 1.70 |
| 2008-03-31 | $5.24B | $3.39B | 1.55 |
| 2007-12-31 | $5.94B | $3.25B | 1.83 |
| 2007-09-30 | $4.69B | $3.38B | 1.39 |
| 2007-06-30 | $4.94B | $2.97B | 1.66 |
| 2007-03-31 | $4.58B | $2.37B | 1.93 |
| 2006-12-31 | $6.03B | $2.63B | 2.29 |
| 2006-09-30 | $4.75B | $2.45B | 1.94 |
| 2006-06-30 | $4.41B | $2.17B | 2.03 |
| 2006-03-31 | $2.87B | $2.04B | 1.41 |
| 2005-12-31 | $2.63B | $1.48B | 1.78 |
| 2005-09-30 | $2.76B | $1.14B | 2.42 |
| 2005-06-30 | $2.72B | $1.76B | 1.55 |
| 2005-03-31 | $2.76B | $1.78B | 1.55 |
| 2004-12-31 | $3.29B | $2.61B | 1.26 |
| 2004-09-30 | $3.02B | $1.87B | 1.62 |
| 2004-06-30 | $2.67B | $1.59B | 1.69 |
| 2004-03-31 | $1.99B | $1.74B | 1.14 |
| 2003-12-31 | $1.88B | $1.39B | 1.35 |
| 2003-09-30 | $1.51B | $1.44B | 1.05 |
| 2003-06-30 | $1.38B | $1.11B | 1.24 |
| 2003-03-31 | $1.24B | $1.09B | 1.14 |
| 2002-12-31 | $1.21B | $0.92B | 1.31 |
| 2002-09-30 | $1.17B | $1.03B | 1.14 |
| 2002-06-30 | $1.07B | $1.06B | 1.01 |
| 2002-03-31 | $1.12B | $0.89B | 1.26 |
| 2001-12-31 | $1.11B | $0.83B | 1.33 |
| 2001-09-30 | $1.03B | $0.94B | 1.09 |
| 2001-06-30 | $1.00B | $1.13B | 0.88 |
| 2001-03-31 | $1.06B | $0.90B | 1.18 |
| 2000-12-31 | $0.99B | $0.82B | 1.21 |
| 2000-09-30 | $0.94B | $0.80B | 1.16 |
| 2000-06-30 | $0.96B | $0.93B | 1.03 |
| 2000-03-31 | $1.02B | $1.04B | 0.97 |
| 1999-12-31 | $1.06B | $1.06B | 1.00 |
| 1999-09-30 | $1.10B | $1.04B | 1.05 |
| 1999-06-30 | $1.19B | $0.95B | 1.26 |
| 1999-03-31 | $1.30B | $1.61B | 0.81 |
| 1998-12-31 | $1.27B | $1.62B | 0.78 |
| 1998-09-30 | $1.37B | $2.64B | 0.52 |
| 1998-06-30 | $1.26B | $0.37B | 3.46 |
| 1998-03-31 | $1.20B | $0.38B | 3.15 |
| 1997-12-31 | $1.06B | $0.81B | 1.32 |
| 1997-09-30 | $1.00B | $0.67B | 1.50 |
| 1997-06-30 | $0.91B | $0.67B | 1.35 |
| 1997-03-31 | $0.76B | $0.46B | 1.67 |
| 1996-12-31 | $0.75B | $0.46B | 1.62 |
| 1996-09-30 | $0.64B | $0.49B | 1.30 |
| 1996-06-30 | $0.58B | $0.47B | 1.25 |
| 1996-03-31 | $0.57B | $0.41B | 1.39 |
| 1995-12-31 | $0.54B | $0.27B | 1.99 |
| 1995-09-30 | $0.46B | $0.14B | 3.32 |
| 1995-06-30 | $0.53B | $0.25B | 2.09 |
| 1995-03-31 | $0.52B | $0.29B | 1.79 |
| 1994-12-31 | $0.26B | $0.07B | 3.58 |
| 1994-09-30 | $0.26B | $0.06B | 4.08 |
| 1994-06-30 | $0.24B | $0.05B | 4.44 |
| 1994-03-31 | $0.23B | $0.06B | 3.69 |
| 1993-12-31 | $0.22B | $0.06B | 3.79 |
| 1993-09-30 | $0.21B | $0.06B | 3.58 |
| 1993-06-30 | $0.22B | $0.05B | 4.26 |
| 1993-03-31 | $0.26B | $0.05B | 5.29 |
| 1992-12-31 | $0.24B | $0.04B | 5.55 |
| 1992-09-30 | $0.22B | $0.05B | 4.80 |
| 1992-06-30 | $0.21B | $0.03B | 7.76 |
| 1992-03-31 | $0.00B | 0.00 | |
| 1991-12-31 | $0.09B | $0.03B | 3.47 |
| 1990-12-31 | $0.06B | $0.03B | 1.70 |
| 1989-12-31 | $0.00B | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $149.593B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $218.907B | 25.23 |
| EssilorLuxottica (ESLOY) | France | $167.835B | 0.00 |
| Stryker (SYK) | United States | $135.768B | 26.96 |
| Medtronic (MDT) | Ireland | $118.854B | 16.76 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.878B | 0.00 |
| Agilent Technologies (A) | United States | $41.493B | 26.85 |
| ResMed (RMD) | United States | $36.500B | 25.26 |
| GE HealthCare Technologies (GEHC) | United States | $33.472B | 16.01 |
| Koninklijke Philips (PHG) | Netherlands | $27.202B | 17.77 |
| Terumo (TRUMY) | Japan | $24.340B | 28.84 |
| Insulet (PODD) | United States | $22.536B | 69.94 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.585B | 10.97 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.234B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $11.495B | 0.00 |
| Baxter (BAX) | United States | $9.124B | 7.37 |
| Bio-Rad Laboratories (BIO) | United States | $8.292B | 29.81 |
| Demant (WILYY) | Denmark | $7.359B | 0.00 |
| ICU Medical (ICUI) | United States | $3.437B | 21.82 |
| Lantheus Holdings (LNTH) | United States | $3.361B | 10.24 |
| Haemonetics (HAE) | United States | $3.299B | 14.68 |
| Envista Holdings (NVST) | United States | $3.297B | 18.92 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.120B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $2.907B | 13.26 |
| LeMaitre Vascular (LMAT) | United States | $1.992B | 40.09 |
| Curaleaf Holdings (CURLF) | Canada | $1.977B | 0.00 |
| Perrigo (PRGO) | Ireland | $1.961B | 4.91 |
| Phibro Animal Health (PAHC) | United States | $1.858B | 18.56 |
| Green Thumb Industries (GTBIF) | United States | $1.612B | 70.64 |
| AtriCure (ATRC) | United States | $1.590B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.471B | 0.00 |
| Neogen (NEOG) | United States | $1.382B | 26.50 |
| Kestra Medical Technologies (KMTS) | United States | $1.359B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.340B | 8.62 |
| AdaptHealth (AHCO) | United States | $1.272B | 18.43 |
| BioLife Solutions (BLFS) | United States | $1.266B | 375.57 |
| InMode (INMD) | Israel | $0.923B | 10.43 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.792B | 0.00 |
| Valneva SE (VALN) | France | $0.764B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.500B | 17.23 |
| SNDL (SNDL) | Canada | $0.491B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.474B | 0.00 |
| Evolus (EOLS) | United States | $0.457B | 0.00 |
| Omeros (OMER) | United States | $0.449B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.438B | 0.00 |
| CeriBell (CBLL) | United States | $0.437B | 0.00 |
| Surmodics (SRDX) | United States | $0.391B | 0.00 |
| Cerus (CERS) | United States | $0.307B | 0.00 |
| Brainsway (BWAY) | Israel | $0.306B | 62.00 |
| Canopy Growth (CGC) | Canada | $0.305B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.294B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.286B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.263B | 155.67 |
| High Tide (HITI) | Canada | $0.262B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.254B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.251B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.249B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.243B | 19.36 |
| Quanterix (QTRX) | United States | $0.238B | 0.00 |
| Owens & Minor (OMI) | United States | $0.228B | 2.29 |
| Organigram Global (OGI) | Canada | $0.222B | 0.00 |
| Exagen (XGN) | United States | $0.214B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.210B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.199B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.184B | 16.18 |
| FitLife Brands (FTLF) | United States | $0.174B | 21.46 |
| OraSure Technologies (OSUR) | United States | $0.167B | 0.00 |
| Apyx Medical (APYX) | United States | $0.157B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.140B | 0.00 |
| Biote (BTMD) | United States | $0.122B | 4.92 |
| Sharps Technology (STSS) | United States | $0.114B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.106B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 0.00 |
| Fonar (FONR) | United States | $0.093B | 13.49 |
| MacroGenics (MGNX) | United States | $0.090B | 0.00 |
| Agape ATP (ATPC) | $0.062B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.055B | 32.00 |
| Nephros (NEPH) | United States | $0.046B | 33.00 |
| Cytosorbents (CTSO) | United States | $0.045B | 0.00 |
| Jin Medical (ZJYL) | China | $0.041B | 0.00 |
| Veru (VERU) | United States | $0.038B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.037B | 0.00 |
| Zynex (ZYXI) | United States | $0.036B | 0.00 |
| Bonk (BNKK) | United States | $0.034B | 0.00 |
| United-Guardian (UG) | United States | $0.029B | 14.65 |
| Modular Medical (MODD) | United States | $0.028B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| INLIF (INLF) | China | $0.011B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.007B | 0.00 |
| Flora Growth (FLGC) | United States | $0.006B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| Akanda (AKAN) | Canada | $0.001B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |